SKYE: רווח למניה בשנים עשר החודשים האחרונים Skye Bioscience, Inc.

Is it worth investing in the innovative cannabinoid drug ecosystem of Skye Bioscience, Inc. (SKYE)? The GURU.Markets platform features this chart, where TTM net income per share demonstrates the asset's dynamics, and the value of -7.62 expresses the metric level. Skye Bioscience, Inc. (SKYE) is developing treatments for obesity and glaucoma, targeting the ophthalmology market. Management is currently actively adapting its strategy while maintaining shareholder confidence.
פילוחים אנליטיים ודוחות נתונים של חברת Skye Bioscience (SKYE)

Net income per share is critical for constructing a high-quality portfolio, calculated by dividing a company's total income over the last 12 months by the total number of outstanding securities. For Skye Bioscience, Inc. (SKYE), which develops non-psychoactive obesity treatments, the trailing twelve-month net income per share trend reflects the efficiency of commercializing innovations in CB1 receptors.